본문 바로가기
KERD
논문KCI 등재

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6- Year Follow-Up Result

Shin Kim|Sang Hee Kim|Jin Hee Ahn|Woo Kun Kim|Hee Jung Sohn|Gyeong Won Lee|Hye Jin Kang|Sung Bae Kim|Sang We Kim|Cheol won Suh
대한암학회 (Korean Cancer Association)|2005.02|Cancer Research and Treatment|제37권 제1호|pp. 24-30

3

조회

0

다운로드

1

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Purpose: The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients. Materials and Methods: From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1,500 mg/m2/day, thiotepa 125 mg/m2/day and carboplatin 200 mg/m2/day intravenously for 4 consecutive days Results: After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS. Conclusion: HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit

참고문헌 (25)

  1. "Diverseprognosis in metastatic breast cancer", pp.33~8 (1989)
  2. "The importance of dose intensity in chemotherapyof metastatic breast cancer", 2, pp.1281~8 (1984)
  3. "High-dose combination alkylating agents with bonemarrow support as initial treatment for metastatic breast cancer", 6, pp.1368~76 (1988)
  4. "High-dose chemotherapy with reinfusion ofpurged autologous bone marrow following dose-intense inductionas initial therapy for metastatic breast cancer", 83, pp.920~6 (1991)
  5. "A phase ii study of high-dose cyclophosphamide,thiotepa,and carboplatin with autologous marrow support in womenwith measurable advanced breast cancer responding tostandard-dose therapy", 10, pp.102~10 (1992)
  6. "A large, prospective, randomized trial ofhigh-dose combination alkylating agents (CPB) with autologouscellular support (ABMS) as consolidation for patientswith metastatic breast cancer achieving complete remission afterintensive doxorubicin-based induction therapy (AFM).", 16, pp.121~149 (1996)
  7. "The verdict is not in yet Analysis of the randomizedtrials of high-dose chemotherapy for breast cancer", pp.201~11 (2003)
  8. "High-dose chemotherapy (HD-CT) with hematopoieticstem cells transplantation (HSCT) for metastatic breastcancer (MBC) results of the French protocol PEGASE 04.", 18, pp.43a~161 (1999)
  9. "Improved survival with consolidation high-dose cyclophosphamide,cisplatin and carmustine (HD-CPB) comparedwith observation in women with metastatic breast cancer(MBC) and only bone metastases treated with induction adriamycin,5-fluorouracil and methotrexate (AFM) A phase IIIprospective randomized comparative trial.", 19, pp.48a~184 (2000)
  10. "Conventional-dose chemotherapy comparedwith high-dose chemotherapy plus autologous hematopoieticstem-cell transplantation for metastatic breast cancer. The PhiladelphiaBone Marrow", 342, pp.1069~76 (2000)
  11. "Conventional-dose chemotherapy comparedwith high-dose chemotherapy (HDC) plus autologous stem-celltransplantation (SCT) for metastatic breast cancer: 5-year updateof the ‘Philadelphia Trial' (PBT-1).", 21, pp.48a~169 (2002)
  12. "A randomized trial of high-dose chemotherapy (HDC)with autologous peripheral blood stem cell support (ASCT)compared to standard therapy in women with metastatic breastcancer: a National Cancer Institute of Canada (NCIC) clinicaltrial group study", 20, pp.21a~ (2001)
  13. "High dose thiotepa (TTP) cyclophosphamide (CPM)and stem cell transplantation after 4 FEC 100 compared with4 FEC alone allowed a better disease free survival but the sameoverall survival in first line chemotherapy for metastatic breastcancer. Results of the PEGASE 03 French Protocol.", 21, pp.42a~167 (2002)
  14. "Randomized trial of up front tandem highdosechemotherapy (HD) compared to standard chemotherapywith doxorubicin and paclitaxel (AT) in metastatic breast cancer(MBC).", 21, pp.43a~171 (2002)
  15. "High dose cyclophosphamide,thiotepa,and carboplatin followedby autologous peripheral stem cell rescue in patientswith responsive metastatic or high-risk primary breast cancer", 30, pp.100~5 (1998)
  16. "Lowdoselenograstim to enhance engraftment after autologous stemcell transplantation:a prospective randomized evaluation oftwo different fixed doses", 44, pp.533~8 (2004)
  17. "Response criteria for phase II studies of supratentorial malignantglioma", 8, pp.1277~80 (1990)
  18. "Impact of selection process on responserate and long-term survival of potential high-dose chemotherapycandidates treated with standard-dose doxorubicincontainingchemotherapy in patients with metastatic breastcancer", 15, pp.3171~7 (1997)
  19. "High-dose chemotherapywith hematopoietic rescue as primary treatment formetastatic breast cancer: a randomized trial.", 13, pp.2483~9 (1995)
  20. "Commentary on PBT-1 study ofhigh-dose consolidation versus standard therapy in metastaticbreast cancer", 17, pp.22~4 (1999)
  21. "High-dose versus standard chemotherapy inmetastatic breast cancer:comparison of cancer and leukemiagroup b trials with data from the autologous blood and marrowtransplant registry", 20, pp.743~50 (2002)
  22. "Factors correlated with progression-free survivalafter high-dose chemotherapy and hematopoietic stem celltransplantation for metastatic breast cancer", 282, pp.1335~43 (1999)
  23. "Prognostic and predictive factors for patientswith metastatic breast cancer undergoing aggressive inductiontherapy followed by high-dose chemotherapy with autologousstem-cell support", 17, pp.3064~74 (1999)
  24. "High-dose chemotherapy (CTM) for breast cancer.", 26, pp.257~68 (2000)
  25. "Metastasectomy as a cytoreductive strategyfor treatment of isolated pulmonary and hepatic metastasesfrom breast cancer", 8, pp.35~42 (1999)

관련 논문AI추천

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with ..Cheolwon Suh, Gyeong-Won Lee, Hee-Jung Sohn, Jin-Hee Ahn, Sang-Hee Kim, Sang-We Kim, Shin Kim, Sung-Bae Kim, Woo Kun Kim대한암학회 · Cancer Research and Treatment2005 · 제37권 제3호Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients김민경, Byung Ho Son, Gyungyub Gong, Hak-Hee Kim, Jin Hee Ahn, Jung-Shin Lee, Sei-Hyun Ahn, Soon Im Lee, Sung-Bae Kim, Woo Kun Kim, Yoon-Koo Kang대한암학회 · Cancer Research and Treatment2006 · 제38권 제4호Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast CancerByung Soo Kim, Chang Ok Suh, Gwi Eon Kim, Hyun Cheol Chung, Jae Kyung Roh, Joo Hyuk Sohn, Nae Choon Yoo, Sun Young Rha, Woo Ick Jang, Yong Tai Kim대한암학회 · Cancer Research and Treatment2003 · 제35권 제3호Prognostic Factors in Non-Hodgkin’s Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center ExperienceCheolwon Suh, Eun Kyung Kim, Geundoo Jang, Hee Jung Sohn, Hyo Jung Kim, Jooryung Huh, Jung Shin Lee, Ok Bae Ko, Sang Hee Kim, Shin Kim, Wookun Kim대한암학회 · Cancer Research and Treatment2005 · 제37권 제5호High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience장현, 정준원, 한지숙연세대학교의과대학 · Yonsei Medical Journal2006 · 제47권 제5호Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin’s Lymphoma이종욱, Byoung Yong Shim, Chun Choo Kim, In Sook Woo, Jae Ho Byun, Ji Chan Park, Ji Yean Peak, Myung Ah Lee, Sang Young Rho, Sook Hee Hong, Woo Sung Min, Yoon Ho Koh, Young Seon Hong대한암학회 · Cancer Research and Treatment2007 · 제39권 제2호

이 간행물의 다른 논문 (9건)

Biology of SNU Cell LinesJae Gahb Park, Ja Lok Kupp. 1-19Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal NeoplasiaSeok Byung Lim, Jin Myeong Huh, Kyung Hae Jung, Joong Bae Ahn, Hyun Kyung Kim, Dae Hyun Kim, 김대용, Young Hoon Kim, Hee Jin Chang, Jae Gahb Park, Dae Kyung Sohn, Seung Yong Jeong, Hyo Seong Choipp. 20-23Treatment Outcome of Limited Stage Hodgkin's Disease안용찬, 김원석, 강원기, Jung Hun Kangpp. 31-36A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to Weekly Cisplatin Alone Combined with Concurrent Radiotherapy for Locally Advanced Cervical CancerSeung Do Ahn, Joo Hyun Nam, Jung Eun Mok, Young Tak Kim, Heon Jin Park, Sang wook Lee, Young Seok Kim, Seong Soo Shin, Jong Hoon Kim, Eun Kyung Choipp. 37-43Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study곽철, 정현, 이상은, 정창욱, 전황균pp. 44-47
원문 보기